Land: Malta
Sprog: engelsk
Kilde: Medicines Authority
Aurobindo Pharma (Malta) Limited Vault 14, Level 2, Valletta Waterfront, Floriana FRN 1913, Malta
N05AH03
OLANZAPINE 5 mg
TABLET
OLANZAPINE 5 mg
POM
PSYCHOLEPTICS
Authorised
2023-07-20
PACKAGE LEAFLET: INFORMATION FOR THE USER OLANZAPINE AUROBINDO PHARMA 5 MG TABLETS OLANZAPINE AUROBINDO PHARMA 10 MG TABLETS olanzapine READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor or pharmacist. • This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. • If you get any side effects talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET:_ _ 1. What Olanzapine Aurobindo Pharma is and what it is used for 2. What you need to know before you take Olanzapine Aurobindo Pharma 3. How to take Olanzapine Aurobindo Pharma 4. Possible side effects 5. How to store Olanzapine Aurobindo Pharma 6. Contents of the pack and other information 1. WHAT OLANZAPINE AUROBINDO PHARMA IS AND WHAT IT IS USED FOR Olanzapine Aurobindo Pharma contains the active substance olanzapine. Olanzapine Aurobindo Pharma belongs to a group of medicines called antipsychotics and is used to treat the following conditions: • Schizophrenia, a disease with symptoms such as hearing, seeing or sensing things which are not there, mistaken beliefs, unusual suspiciousness, and becoming withdrawn. People with this disease may also feel depressed, anxious or tense. • Moderate to severe manic episodes, a condition with symptoms of excitement or euphoria. Olanzapine Aurobindo Pharma has been shown to prevent recurrence of these symptoms in patients with bipolar disorder whose manic episode has responded to olanzapine treatment. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE OLANZAPINE AUROBINDO PHARMA_ _ DO NOT TAKE OLANZAPINE AUROBINDO PHARMA • If you are allergic (hypersensitive) to olanzapine or any of the other ingredients of this medicine (listed in section 6). An allergic reaction may be recogn Læs hele dokumentet
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Olanzapine Aurobindo Pharma 5 mg tablets Olanzapine Aurobindo Pharma 10 mg tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 5 mg olanzapine. Excipient with known effect : 90.50 mg lactose monohydrate. Each tablet contains 10 mg olanzapine. Excipient with known effect: 181.00 mg lactose monohydrate. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Tablet. Olanzapine Aurobindo Pharma 5 mg Tablets: _[Size: About 6.5 mm]_ Yellow coloured, circular, biconvex uncoated tablets, debossed with ‘OA’ on one side and ‘5’ on the other side. Olanzapine Aurobindo Pharma 10 mg Tablets: _[Size: About 8 mm]_ Yellow coloured, circular, biconvex uncoated tablets, debossed with ‘OA’ on one side and ‘10’ on the other side. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS _ _ _Adults _ Olanzapine is indicated for the treatment of schizophrenia. Olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response. Olanzapine is indicated for the treatment of moderate to severe manic episode. In patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder (see section 5.1). 4.2 POSOLOGY AND METHOD OF ADMINISTRATION _ _ _Adults _ Schizophrenia: The recommended starting dose for olanzapine is 10 mg/day. Manic episode: The starting dose is 15 mg as a single daily dose in monotherapy or 10 mg daily in combination therapy (see section 5.1). Preventing recurrence in bipolar disorder: The recommended starting dose is 10 mg/day. For patients who have been receiving olanzapine for treatment of manic episode, continue therapy for preventing recurrence at the same dose. If a new manic, mixed, or depressive episode occurs, olanzapine treatment should be continued (with dose optimisation as needed), with supplementary therapy to treat mood sym Læs hele dokumentet